Skip to main content
SpringerLink
Log in

Immunotherapy and Novel Agents on the Horizon for the Treatment of Prostate Cancer

  • Chapter
  • First Online:
Chemotherapy and Immunotherapy in Urologic Oncology

  • 544 Accesses

Abstract

Novel treatment agents for prostate cancer are now giving clinicians the resources to individualize patient-specific care in the hopes of increasing survival rates. The availability of genetic sequencing will help differentiate optimal treatments. Immunotherapy includes treatments which stimulate the patient’s own immune system to recognize and attack growing cancer cells. It has been proven to be an effective treatment for various types of cancers, and research has expanded its use in the treatment of prostate cancer. Immune checkpoint inhibitors reactivate pathways so the body can again kill invading cancer cells. Finally, PARP inhibitors block an enzyme used by cancer cells to repair DNA. When used alone, these treatments may not be broadly overly beneficial; however, researchers are using different combinations of the agents to help offer better outcomes in the treatment of advanced prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.

    Article  CAS  Google Scholar 

  2. Full prescribing information. Provenge package insert. Dendroen Pharmaceuticals LLC. 2017. http://www.provengehcp.com/Portals/5/Provenge-PI.pdf. Accessed 22 Jan 2019.

  3. Presenters Gomella L, Delacruz A. Developing strategies for sequencing and combining therapies in advanced prostate cancer. Nursing considerations for implementing a tailored treatment approach. 2017. Sponsored by PleXus Communications [Power Point slides, Lecture Booklet]. Attended lecture 11 Jan 2017.

    Google Scholar 

  4. Provenge infusion checklist. Dendron Pharmaceuticals, LLC. 2014. https://www.provengehcp.com/Portals/5/PDF/Infusion_Checklist.pdf. Accessed 11 Jan 2019.

  5. Patel A, Fong L. Immunotherapy for prostate cancer: where do we go from here?-Part 2: checkpoint inhibitors, immunotherapy combinations, tumor microenvironment modulation, and cell therapies. Oncology (Williston Park). 2018;32(6):65–73.

    Google Scholar 

  6. Goswami S, Aparicio A, Subudhi SK. Immune checkpoint therapies in prostate cancer. Cancer J. 2016;22(2):117–20.

    Article  CAS  Google Scholar 

  7. Katz A. FDA grants rucaparib breakthrough designation for mCRPC. 2018. OncLive. https://www.onclive.com/web-exclusives/fda-grants-rucaparib-breakthrough-designation-for-mcrpc. Accessed 10 Feb 2019.

  8. Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2019;75:88–99.

    Article  Google Scholar 

  9. Yentz S, Morgan T, Reichert Z. The potential role for PARP inhibitors in prostate cancer. Prostate Cancer Advisor, Renal and Urology News. 2018. August 10, 2018. https://www.renalandurologynews.com/home/news/urology/prostate-cancer/the-potential-role-for-parp-inhibitors-in-prostate-cancer/. Accessed 18 Feb 2019.

  10. Modena A, Ciccarese C, Iacovelli R, Brunelli M, Montironi R, Fiorentino M, Tortara G, Massari F. Immune checkpoint inhibitors and prostate cancer: a new frontier? Oncol Rev. 2016;10(1):293. https://doi.org/10.4081/oncol.2016.293.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration resistant prostate cancer. N Engl J Med. 2020;382;2091–102.

    Google Scholar 

  12. Anassi E, Ndefo U. Sipuleucel-T (Provenge) injection. The first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. Pharm Ther. 2011;36(4):197–202.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Thomas Jefferson University Hospital, Department of Urology, Philadelphia, PA, USA

    Suzanne Barron & Mark J. Mann

Authors
  1. Suzanne Barron
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark J. Mann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Suzanne Barron .

Editor information

Editors and Affiliations

  1. Department of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA

    Edouard J. Trabulsi

  2. Department of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA

    Costas D. Lallas

  3. Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA

    Anne E. Lizardi-Calvaresi

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Barron, S., Mann, M.J. (2021). Immunotherapy and Novel Agents on the Horizon for the Treatment of Prostate Cancer. In: Trabulsi, E.J., Lallas, C.D., Lizardi-Calvaresi, A.E. (eds) Chemotherapy and Immunotherapy in Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-52021-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-52021-2_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-52020-5

  • Online ISBN: 978-3-030-52021-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation